SNBP - Acceleron's Label Expansion And Other News: The Good Bad And Ugly Of Biopharma
Acceleron Granted FDA Approval for Luspatercept Label Expansion
Acceleron (XLRN) reported that the FDA has granted approval for the use of Reblozyl for treating anemia in certain adult patients with very low to intermediate risk myelodysplastic syndromes. These are the patients who did not respond to treatment with an erythropoiesis stimulating agent and require minimum two red blood cell units over eight weeks. Acceleron is collaborating with Bristol Myers Squibb for developing this drug candidate.
Acceleron noted that the drug is not indicated for use as a substitute for RBC transfusions in patients